The 13 references in paper A. Zaritskey Yu., E. Chernyaeva V., K. Kaplanov D., R. Ivanov A., S. Alekseev M., А. Зарицкий Ю., Е. Черняева В., К. Капланов Д., Р. Иванов А., С. Алексеев М. (2015) “НАЧАЛО ЭРЫ ПРИМЕНЕНИЯ БИОАНАЛОГОВ МОНОКЛОНАЛЬНЫХ АНТИТЕЛ В ОНКОЛОГИИ: СОВРЕМЕННЫЕ МЕЖДУНАРОДНЫЕ РЕКОМЕНДАЦИИ И РЕЗУЛЬТАТЫ ИССЛЕДОВАНИЯ ПЕРВОГО РОССИЙСКОГО БИОАНАЛОГА РИТУКСИМАБА У БОЛЬНЫХ В-КЛЕТОЧНОЙ НЕХОДЖКИНСКОЙ ЛИМФОМОЙ // THE BEGINNING OF THE NEW ERA OF MONOCLONAL ANTIBODIES BIOSIMILARS USE IN ONCOLOGY: CURRENT INTERNATIONAL GUIDELINES AND THE RESULTS OF CLINICAL TRIAL OF THE FIRST RUSSIAN RITUXIMAB BIOSIMILAR IN PATIENTS WITH B-CELL NON-HODGKIN’S LYMPHOMA” / spz:neicon:modonc:y:2014:i:2:p:38-44

1
Состояние онкологической помощи населению России в 2012 г. Под ред. А.Д.Каприна, В.В.Старинского, Г.В.Петровой. М.: ФГБУ МНОИ им. П.А.Герцена Минздрава России, 2013.
(check this in PDF content)
2
Поддубная И.В. Биосимиляры: новые возможности современной лекарственной терапии опухолей. Соврем. онкология. 2011; 4.
(check this in PDF content)
3
Czuczman MS, Grillo-Lopez AJ, White CA et al. Treatment of patients with lowgrade B-cell lymphoma with the combination of chimeric anti-CD20 monoclonal antibody and CHOP chemotherapy. J Clin Oncol 1999; 17 (1): 268–76.
(check this in PDF content)
4
Czuczman MS, Weaver R, Alkuzweny B et al. Prolonged clinical and molecular remission in patients with low-grade or follicular non-Hodgkin’s lymphoma treated with Rituximab plus CHOP chemotherapy: 9-year follow-up. J Clin Oncol 2004; 22 (23): 4711–6.
(check this in PDF content)
5
Smith I, Procter M, Gelber RD et al. HERA study team. 2-year follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer: a randomised controlled trial. Lancet 2007; 369 (9555): 29–36.
(check this in PDF content)
6
Государственный реестр предельных отпускных цен на лекарственные средства Минздрава России (данные от 27.03.2014 г.); http:// grls.rosminzdrav.ru/PriceLims.aspx
(check this in PDF content)
7
Инструкция по медицинскому применению препарата Мабтера. РУПN013127/01.
(check this in PDF content)
8
Инструкция по медицинскому применению препарата Герцептин. РУПN012038/01.
(check this in PDF content)
9
Guideline on similar biological medicinal products containing monoclonal antibodies – non-clinical and clinical issues. EMA: London, UK 2012; EMA/CHMP/BMWP/403543/2010
(check this in PDF content)
10
Guideline on Similar Biological Medicinal Products Containing Biotechnology-Derived Proteins as Active Substance: Non-Clinical and Clinical Issues. EMA: London, UK 2006; EMEA/CHMP/BMWP/42832
(check this in PDF content)
11
Mellstedt H. Clinical considerations for biosimilar antibodies. Europ J Cancer Suppl 2013; 11 (3): 1–11.
(check this in PDF content)
12
Maloney DG et al. IDEC-C2B8 (Rituximab) anti-CD20 monoclonal antibody therapy in patients with relapsed low-grade non-Hodgkin's lymphoma. Blood 1997; 90 (6): 2188–95.
(check this in PDF content)
13
Hainsworth JD. Rituximab as first-line and maintenance therapy for patients with indolent non-hodgkin's lymphoma. J Clin Oncol 2002; 20 (20): 4261–7.
(check this in PDF content)